Arbutus announces five abstracts on imdusiran and AB-101 accepted at EASL 2025, including late-breaker

Arbutus Biopharma Corp

Five abstracts accepted for poster presentation at EASL Congress 2025 (May 7-10, Amsterdam); one late-breaker (LB25153).
Abstract 1768: IM-PROVE I study shows HBsAg at baseline and NA discontinuation associated with functional cure in CHB subjects.
Abstract 2043: Rapid HBV RNA decline during imdusiran lead-in, then transient increases with interferon, linked to HBsAg seroclearance.
AB-101 (oral PD-L1 inhibitor) data: well-tolerated in healthy/subjects, dose-responsive PD-L1 RO, high liver biodistribution.
Late-breaker LB25153: off-treatment antiviral efficacy and safety of repeat imdusiran + VTP-300 with/without nivolumab in CHB.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.